Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis

Next Previous
Search
Trial Profile

Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Aspirin
  • Indications Essential thrombocythaemia; Polycythaemia vera; Venous thrombosis
  • Focus Therapeutic Use
  • Sponsors Roche

Most Recent Events

  • 08 Dec 2020 Results of pooled analysis (of data from MPN-RC 111 and MPN-RC 112 studies) assessing the Symptom burden and quality of life in high-risk essential Thrombocythemia and Polycythemia Vera patients presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
  • 06 Nov 2019 Results assessing activity of pegylated interferon alfa-2a (PEG) in two trials (MPD-RC 111; NCT01259817 and MPD-RC 112; NCT01258856) released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
  • 12 Dec 2017 Results assessing MPN symptom impact and quality of life, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top